Artificial intelligence is pushing deeper into medicine, spanning the earliest stages of drug discovery through to the delivery of care itself.
On the discovery side, several efforts are underway at once. Healthcare Digital reports that pharmaceutical giant Bayer is using AI to advance drug discovery through a partnership with Iambic. Separately, The Chemical Engineer reports that Anthropic has launched an AI tool designed to speed up drug discovery. And in India, the New Indian Express reports that Acubiosys, a Hyderabad-based biotech startup, has developed two phytomedicines for psoriasis that it describes as enabled by both artificial intelligence and nanotechnology.
The more striking shift is happening closer to patients. According to Endpoints News, medicine is heading toward a future in which certain parts of care are delivered without any humans involved. The outlet points to Cadence, a company that raised a $100 million Series C last week and is betting it can manage aspects of care using AI.
Taken together, the sources sketch a spectrum: AI as a laboratory accelerator that helps scientists find and design new compounds faster, and AI as a front-line tool that could take over slices of clinical work traditionally done by clinicians.
Both ends carry weight. Faster discovery, as pursued by Bayer, Anthropic and startups like Acubiosys, could shorten the long road from idea to treatment. Autonomous delivery, as framed by Endpoints News around Cadence's funding, raises harder questions about oversight, safety and trust when software rather than a person is making care decisions.
Why it matters: the same technology now reshaping how drugs are invented is beginning to reach the point of care, meaning patients themselves — not just researchers — may soon feel AI's direct hand in their treatment.